[Home](https://github.com/mm80843/T3.5/blob/pages/index.md) >> Class: [Risk](https://github.com/mm80843/T3.5/tree/pages/docs/Risk/index.md) >> Individual ID:PBN__Risk_1139 

# __Lack of drug therapy options__

## Articles mentionning the risk

* [An environmental and health perspective for COVID-19 outbreak: Meteorology and air quality influence, sewage epidemiology indicator, hospitals disinfection, drug therapies and recommendations](https://github.com/mm80843/T3.5/blob/pages/Article/PBN__Article_270.md)

## Category to which it belongs

* [Inadequate resources, staff, facilities, training, coordination, and preparedness contribute to the inefficient and ineffective response to various challenges and needs.](https://github.com/mm80843/T3.5/blob/pages/PBNCategory/PBN__PBNCategory_78.md)

## Closest similar item

* [Ineffective non-pharmaceutical interventions](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_2165.md)
* [Insufficient non-pharmaceutical interventions](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_2684.md)
* [Lack of access to pharmaceutical interventions](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1849.md)
* [Lack of accessibility of pharmaceutical interventions in developing countries](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1590.md)
* [Lack of drug therapies for covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1151.md)
* [Lack of effective drugs](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1478.md)
* [Lack of effective pharmaceutical response](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1589.md)
* [Lack of effective treatment](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_2046.md)
* [Lack of novel treatment options](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_935.md)
* [Lack of treatment and resources](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_727.md)

## Description of the risk

Limited evidence of the efficacy of drug therapies for treating COVID-19

## Is the risk affecting GBN scales

* [No](https://github.com/mm80843/T3.5/blob/pages/ISO_Scale/PBN__ISO_Scale_0.md)

## Mitigations of this risk

* [Conduct clinical trials to determine the efficacy of drug therapies, develop new therapeutics](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_1594.md)

## Name of the risk

Delay in effective treatment and management of COVID-19 cases

## People affected by this risk

* [Individuals infected with covid-19](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_684.md)

## Stakeholders who can mitigate this risk

* [Medical researchers](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_685.md)
* [Pharmaceutical companies](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_124.md)

## Technologies linked to the risk

* [Anti-inflammatory drugs](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_236.md)
* [Anti-malaria drugs](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_237.md)
* [Antiviral drugs](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_238.md)

## This Risk belongs to this RiskGroup

* [Public health risks](https://github.com/mm80843/T3.5/blob/pages/RiskGroup/PBN__RiskGroup_3.md)

## This Risk belongs to this RiskSubgroup

* [Lack of effective medical solutions](https://github.com/mm80843/T3.5/blob/pages/RiskSubgroup/PBN__RiskSubgroup_37.md)

## Type of impact of the risk (according to ISO37100)

* [Health and care](https://github.com/mm80843/T3.5/blob/pages/ISO_Purpose/PBN__ISO_Purpose_0.md)

## Type of purpose of the risk (according to ISO37100)

* [Safety and security](https://github.com/mm80843/T3.5/blob/pages/ISO_Impact/PBN__ISO_Impact_0.md)

## Type of the risk

* [Physical](https://github.com/mm80843/T3.5/blob/pages/RiskHealth/PBN__RiskHealth_0.md)

## Property: has_RiskType

* [Technological](https://github.com/mm80843/T3.5/blob/pages/RiskType/PBN__RiskType_5.md)

